These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34082764)

  • 1. Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature.
    Baldo F; Brena M; Carbogno S; Minoia F; Lanni S; Guez S; Petaccia A; Agostoni C; Cimaz R; Filocamo G
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):80. PubMed ID: 34082764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juvenile idiopathic arthritis in infants with Harlequin Ichthyosis: two cases report and literature review.
    Auriti C; Rotunno R; Diociaiuti A; Manzoni SM; Uva A; Bersani I; Santisi A; Dotta A; El Hachem M
    Ital J Pediatr; 2020 Apr; 46(1):44. PubMed ID: 32293521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis.
    Chan YC; Tay YK; Tan LK; Happle R; Giam YC
    Pediatr Dermatol; 2003; 20(5):421-6. PubMed ID: 14521561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harlequin ichthyosis and juvenile idiopathic arthritis: a rare combination.
    Clement SA; Burrows NP; Sansome A; Hazleman BL; Ostör AJ
    Clin Rheumatol; 2007 Mar; 26(3):460-2. PubMed ID: 17119860
    [No Abstract]   [Full Text] [Related]  

  • 5. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total hip replacement in an adolescent patient with harlequin ichthyosis; a case report.
    Beazley JC; Ho K; Ilchyshyn A; Foguet P
    Hip Int; 2011; 21(4):487-9. PubMed ID: 21936072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
    Schmeling H; Mathony K; John V; Keysser G; Burdach S; Horneff G
    Ann Rheum Dis; 2001 Apr; 60(4):410-2. PubMed ID: 11247875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept.
    Öman A; Dicksved J; Engstrand L; Berntson L
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):55. PubMed ID: 33902613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
    Nimmrich S; Horneff G
    Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Windschall D; Müller T; Becker I; Horneff G
    Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.
    Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A
    Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis.
    Maciejewska-Paszek I; Grochowska-Niedworok E; Siwiec A; Gruenpeter A; Dul L; Irzyniec T
    J Int Med Res; 2017 Apr; 45(2):525-532. PubMed ID: 28415953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.
    Mori M; Sugiyama N; Morishima Y; Sugiyama N; Kokubo T; Takei S; Yokota S
    Mod Rheumatol; 2018 Jan; 28(1):101-107. PubMed ID: 28448193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
    Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
    Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.